Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-schisandrin B | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of IGFBP4 mRNA] | CTD | PMID:31150632 | (1->4)-beta-D-glucan | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of IGFBP4 mRNA | CTD | PMID:36331819 | 1,1-dichloroethene | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | vinylidene chloride results in decreased expression of IGFBP4 mRNA | CTD | PMID:26682919 | 1,2-dimethylhydrazine | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of IGFBP4 mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | affects expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Ethinyl Estradiol affects the expression of IGFBP4 mRNA | CTD | PMID:17555576 | 17alpha-ethynylestradiol | decreases expression | EXP | | 6480464 | Ethinyl Estradiol results in decreased expression of IGFBP4 mRNA | CTD | PMID:17108234 | 17alpha-ethynylestradiol | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Ethinyl Estradiol results in increased expression of IGFBP4 protein | CTD | PMID:15817916 | 17beta-estradiol | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Estradiol affects the expression of IGFBP4 mRNA | CTD | PMID:14699072 | 17beta-estradiol | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Estradiol results in increased expression of IGFBP4 mRNA | CTD | PMID:14605097 more ... | 17beta-estradiol | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Estradiol results in increased expression of IGFBP4 mRNA | CTD | PMID:12469912 | 17beta-estradiol | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA more ... | CTD | PMID:12399409 more ... | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin affects the expression of IGFBP4 mRNA | CTD | PMID:20106945 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of IGFBP4 mRNA | CTD | PMID:23639626 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IGFBP4 protein] more ... | CTD | PMID:23639626 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of IGFBP4 mRNA | CTD | PMID:21496263 and PMID:21632981 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of IGFBP4 mRNA | CTD | PMID:21496263 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of IGFBP4 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of IGFBP4 mRNA | CTD | PMID:22298810 and PMID:34747641 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of IGFBP4 mRNA | CTD | PMID:19465110 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of IGFBP4 mRNA | CTD | PMID:19901195 | 2,4,6-trinitrobenzenesulfonic acid | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IGFBP4 mRNA] | CTD | PMID:18200517 | 2,4,6-trinitrobenzenesulfonic acid | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Trinitrobenzenesulfonic Acid results in increased expression of IGFBP4 mRNA | CTD | PMID:18200517 | 2-amino-2-deoxy-D-glucopyranose | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Glucosamine results in decreased expression of IGFBP4 mRNA | CTD | PMID:17178593 | 2-butoxyethanol | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | n-butoxyethanol results in decreased expression of IGFBP4 mRNA | CTD | PMID:19812364 | 3,3',4,4',5-pentachlorobiphenyl | decreases expression | EXP | | 6480464 | 3 more ... | CTD | PMID:23196670 | 3,3',4,4'-tetrachlorobiphenyl | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | 3 more ... | CTD | PMID:19467301 | 3,4-methylenedioxymethamphetamine | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | N-Methyl-3 and 4-methylenedioxyamphetamine results in increased expression of IGFBP4 mRNA | CTD | PMID:20188158 | 3-chloropropane-1,2-diol | decreases expression | EXP | | 6480464 | alpha-Chlorohydrin results in decreased expression of IGFBP4 mRNA | CTD | PMID:28522335 | 3-Nitrobenzanthrone | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | 3-nitrobenzanthrone results in increased expression of IGFBP4 mRNA | CTD | PMID:34036453 | 4,4'-sulfonyldiphenol | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | bisphenol S results in increased expression of IGFBP4 mRNA | CTD | PMID:30951980 | 5-azacytidine | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Azacitidine results in increased expression of IGFBP4 mRNA | CTD | PMID:20823114 | 5-fluorouracil | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | CTD | PMID:16896004 | 6-propyl-2-thiouracil | affects expression | EXP | | 6480464 | Propylthiouracil affects the expression of IGFBP4 mRNA | CTD | PMID:24780913 | acetamide | decreases expression | EXP | | 6480464 | acetamide results in decreased expression of IGFBP4 mRNA | CTD | PMID:31881176 | acrylamide | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Acrylamide results in decreased expression of IGFBP4 mRNA | CTD | PMID:32763439 | afimoxifene | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | afimoxifene inhibits the reaction [Estrogens results in increased expression of IGFBP4 mRNA] | CTD | PMID:21233418 | afimoxifene | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | afimoxifene results in increased expression of IGFBP4 mRNA | CTD | PMID:15072547 and PMID:19901195 | aflatoxin B1 | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Aflatoxin B1 affects the expression of IGFBP4 protein | CTD | PMID:20106945 | aflatoxin B1 | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased expression of IGFBP4 mRNA | CTD | PMID:21632981 | aflatoxin B1 | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Aflatoxin B1 results in increased expression of IGFBP4 mRNA | CTD | PMID:19770486 | aldehydo-D-glucosamine | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Glucosamine results in decreased expression of IGFBP4 mRNA | CTD | PMID:17178593 | aldehydo-D-glucose | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Glucose results in decreased expression of IGFBP4 mRNA | CTD | PMID:17178593 | all-trans-retinoic acid | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Tretinoin co-treated with arsenic trioxide] results in decreased expression of IGFBP4 mRNA | CTD | PMID:15894607 | all-trans-retinoic acid | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of IGFBP4 mRNA | CTD | PMID:15894607 and PMID:33167477 | alpha-naphthoflavone | multiple interactions | EXP | | 6480464 | AHR gene mutant form inhibits the reaction [alpha-naphthoflavone results in increased expression of IGFBP4 protein] | CTD | PMID:23639626 | alpha-naphthoflavone | increases expression | EXP | | 6480464 | alpha-naphthoflavone results in increased expression of IGFBP4 protein | CTD | PMID:23639626 | aluminium sulfate (anhydrous) | decreases secretion | ISO | IGFBP4 (Homo sapiens) | 6480464 | aluminum sulfate results in decreased secretion of IGFBP4 protein | CTD | PMID:7685579 | aluminium trifluoride | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | aluminum fluoride results in decreased expression of IGFBP4 mRNA and aluminum fluoride results in decreased expression of IGFBP4 protein | CTD | PMID:11996908 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of IGFBP4 mRNA | CTD | PMID:16483693 | arsenite(3-) | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | Fulvestrant inhibits the reaction [arsenite results in increased expression of IGFBP4 mRNA] | CTD | PMID:31646340 | arsenite(3-) | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | arsenite results in increased expression of IGFBP4 mRNA | CTD | PMID:31646340 | arsenous acid | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Arsenic Trioxide co-treated with Curcumin] results in increased expression of IGFBP4 protein and [Tretinoin co-treated with Arsenic Trioxide] results in decreased expression of IGFBP4 mRNA | CTD | PMID:15894607 and PMID:27430728 | arsenous acid | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Arsenic Trioxide results in increased expression of IGFBP4 protein | CTD | PMID:27430728 | atrazine | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Atrazine results in increased expression of IGFBP4 mRNA | CTD | PMID:22378314 | azoxystrobin | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | azoxystrobin results in decreased expression of IGFBP4 mRNA | CTD | PMID:33512557 | benzo[a]pyrene | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the expression of IGFBP4 mRNA | CTD | PMID:20106945 | benzo[a]pyrene | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of IGFBP4 mRNA | CTD | PMID:32234424 | benzo[a]pyrene | increases methylation | ISO | IGFBP4 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of IGFBP4 promoter | CTD | PMID:27901495 | benzo[a]pyrene | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased expression of IGFBP4 mRNA | CTD | PMID:21632981 | benzo[a]pyrene | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of IGFBP4 mRNA | CTD | PMID:20713471 and PMID:22228805 | benzo[a]pyrene | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of IGFBP4 mRNA | CTD | PMID:19770486 and PMID:21715664 | benzo[b]fluoranthene | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | benzo(b)fluoranthene results in decreased expression of IGFBP4 mRNA | CTD | PMID:26377693 | beta-D-glucosamine | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Glucosamine results in decreased expression of IGFBP4 mRNA | CTD | PMID:17178593 | bicalutamide | increases expression | EXP | | 6480464 | bicalutamide results in increased expression of IGFBP4 mRNA | CTD | PMID:10604720 | bis(2-ethylhexyl) phthalate | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Diethylhexyl Phthalate results in increased expression of IGFBP4 mRNA | CTD | PMID:31163220 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Diethylhexyl Phthalate results in decreased expression of IGFBP4 mRNA | CTD | PMID:31211961 | bisphenol A | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | bisphenol A results in increased expression of IGFBP4 mRNA | CTD | PMID:16474171 and PMID:21826169 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of IGFBP4 mRNA | CTD | PMID:30816183 more ... | bisphenol A | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | bisphenol A results in increased expression of IGFBP4 mRNA | CTD | PMID:30951980 more ... | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of IGFBP4 mRNA | CTD | PMID:25181051 | bisphenol A | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of IGFBP4 mRNA | CTD | PMID:25047013 | bisphenol F | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | bisphenol F results in increased expression of IGFBP4 mRNA | CTD | PMID:30951980 | bucladesine | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA | CTD | PMID:20823114 | butyric acid | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Butyric Acid results in increased expression of IGFBP4 mRNA | CTD | PMID:34581912 | cadmium atom | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Cadmium results in increased expression of IGFBP4 mRNA | CTD | PMID:21120746 and PMID:31646340 | cadmium atom | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | Fulvestrant inhibits the reaction [Cadmium results in increased expression of IGFBP4 mRNA] | CTD | PMID:31646340 | cadmium dichloride | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | Acetylcysteine inhibits the reaction [Cadmium Chloride results in decreased secretion of IGFBP4 protein] | CTD | PMID:26138014 | cadmium dichloride | decreases secretion | ISO | IGFBP4 (Homo sapiens) | 6480464 | Cadmium Chloride results in decreased secretion of IGFBP4 protein | CTD | PMID:26138014 | calciol | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Cholecalciferol results in increased expression of IGFBP4 mRNA | CTD | PMID:17170073 | cannabidiol | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Cannabidiol results in decreased expression of IGFBP4 mRNA | CTD | PMID:21542829 | cannabidiol | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IGFBP4 mRNA] | CTD | PMID:27256343 | carbon nanotube | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | CGP 52608 | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to IGFBP4 gene] | CTD | PMID:28238834 | ciguatoxin CTX1B | affects expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Ciguatoxins affects the expression of IGFBP4 mRNA | CTD | PMID:18353800 | cisplatin | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of IGFBP4 mRNA | CTD | PMID:30871063 | cisplatin | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Cisplatin results in decreased expression of IGFBP4 mRNA | CTD | PMID:27392435 | cisplatin | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Cisplatin results in decreased expression of IGFBP4 mRNA | CTD | PMID:21151649 | clofibrate | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Clofibrate results in decreased expression of IGFBP4 mRNA | CTD | PMID:17585979 | cobalt dichloride | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | cobaltous chloride results in decreased expression of IGFBP4 mRNA | CTD | PMID:19320972 | cobalt dichloride | decreases expression | EXP | | 6480464 | cobaltous chloride results in decreased expression of IGFBP4 mRNA | CTD | PMID:24386269 | copper(II) sulfate | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of IGFBP4 mRNA | CTD | PMID:19549813 | coumestrol | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:18310284 and PMID:19167446 | cumene | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [cumene co-treated with KRAS gene mutant form] results in decreased expression of IGFBP4 mRNA | CTD | PMID:18648096 | curcumin | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IGFBP4 mRNA] | CTD | PMID:18200517 | curcumin | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [arsenic trioxide co-treated with Curcumin] results in increased expression of IGFBP4 protein | CTD | PMID:27430728 | cycloheximide | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Cycloheximide results in increased expression of IGFBP4 mRNA | CTD | PMID:15072547 | cycloheximide | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA | CTD | PMID:15072547 | cyclophosphamide | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | CTD | PMID:16896004 | cyclosporin A | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of IGFBP4 mRNA | CTD | PMID:21632981 | D-glucose | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Glucose results in decreased expression of IGFBP4 mRNA | CTD | PMID:17178593 | daidzein | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | daidzein results in increased expression of IGFBP4 mRNA | CTD | PMID:15757668 | decabromodiphenyl ether | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | decabromobiphenyl ether affects the expression of IGFBP4 mRNA | CTD | PMID:24834073 | dexamethasone | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Dexamethasone results in decreased expression of IGFBP4 mRNA | CTD | PMID:22733784 | dextran sulfate | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP4 mRNA | CTD | PMID:29950665 | diarsenic trioxide | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Arsenic Trioxide co-treated with Curcumin] results in increased expression of IGFBP4 protein and [Tretinoin co-treated with Arsenic Trioxide] results in decreased expression of IGFBP4 mRNA | CTD | PMID:15894607 and PMID:27430728 | diarsenic trioxide | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Arsenic Trioxide results in increased expression of IGFBP4 protein | CTD | PMID:27430728 | dibenzo[a,l]pyrene | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | dibenzo(a and l)pyrene results in increased expression of IGFBP4 mRNA | CTD | PMID:25908611 | diethylstilbestrol | increases expression | EXP | | 6480464 | Diethylstilbestrol results in increased expression of IGFBP4 mRNA | CTD | PMID:17005392 | dimethylarsinic acid | decreases expression | EXP | | 6480464 | Cacodylic Acid results in decreased expression of IGFBP4 mRNA | CTD | PMID:37567419 | dioxygen | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [Oxygen deficiency co-treated with Oxygen] results in decreased expression of IGFBP4 mRNA more ... | CTD | PMID:25922074 and PMID:30529165 | doxorubicin | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | CTD | PMID:16896004 | doxorubicin | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Doxorubicin results in increased expression of IGFBP4 mRNA | CTD | PMID:29803840 | elemental selenium | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Selenium results in increased expression of IGFBP4 mRNA | CTD | PMID:19244175 | ellagic acid | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Ellagic Acid results in decreased expression of IGFBP4 mRNA | CTD | PMID:12002526 | endosulfan | affects expression | EXP | | 6480464 | Endosulfan affects the expression of IGFBP4 mRNA | CTD | PMID:29391264 | Enterolactone | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IGFBP4 mRNA | CTD | PMID:19167446 | ethanol | affects splicing | ISO | Igfbp4 (Mus musculus) | 6480464 | Ethanol affects the splicing of IGFBP4 mRNA | CTD | PMID:30319688 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of IGFBP4 mRNA | CTD | PMID:21525395 and PMID:26485406 | formaldehyde | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Formaldehyde results in increased expression of IGFBP4 mRNA | CTD | PMID:18045764 | fulvestrant | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Fulvestrant results in decreased expression of IGFBP4 mRNA | CTD | PMID:15072547 and PMID:31646340 | fulvestrant | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | Fulvestrant inhibits the reaction [arsenite results in increased expression of IGFBP4 mRNA] more ... | CTD | PMID:31646340 | genistein | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Genistein results in increased expression of IGFBP4 mRNA | CTD | PMID:15757668 more ... | glucose | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Glucose results in decreased expression of IGFBP4 mRNA | CTD | PMID:17178593 | graphene oxide | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | graphene oxide results in increased expression of IGFBP4 protein | CTD | PMID:33219560 and PMID:33219572 | hydrogen peroxide | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Hydrogen Peroxide results in increased expression of IGFBP4 mRNA | CTD | PMID:32949572 | inulin | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of IGFBP4 mRNA | CTD | PMID:36331819 | isotretinoin | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Isotretinoin results in increased expression of IGFBP4 mRNA | CTD | PMID:20436886 | leflunomide | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | leflunomide results in increased expression of IGFBP4 mRNA | CTD | PMID:28988120 | lipopolysaccharide | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [NAT10 protein affects the susceptibility to Lipopolysaccharides] which affects the expression of IGFBP4 mRNA more ... | CTD | PMID:35811015 and PMID:35877022 | medroxyprogesterone acetate | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA | CTD | PMID:20823114 | methidathion | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | methidathion results in increased expression of IGFBP4 mRNA | CTD | PMID:34813904 | methotrexate | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Methotrexate results in decreased expression of IGFBP4 mRNA | CTD | PMID:24449571 | methoxychlor | affects methylation | EXP | | 6480464 | Methoxychlor affects the methylation of IGFBP4 gene | CTD | PMID:35440735 | N(6)-methyladenosine | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [[METTL3 protein affects the abundance of N-methyladenosine] which affects the methylation of IGFBP4 mRNA] which affects the expression of IGFBP4 protein more ... | CTD | PMID:35971034 | N-acetyl-L-cysteine | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | Acetylcysteine inhibits the reaction [Cadmium Chloride results in decreased secretion of IGFBP4 protein] | CTD | PMID:26138014 | N-nitrosodiethylamine | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Diethylnitrosamine results in increased expression of IGFBP4 mRNA | CTD | PMID:21527772 | nefazodone | decreases expression | EXP | | 6480464 | nefazodone results in decreased expression of IGFBP4 mRNA | CTD | PMID:24136188 | nickel dichloride | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | nickel chloride results in decreased expression of IGFBP4 mRNA | CTD | PMID:12839937 | nickel sulfate | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | nickel sulfate results in decreased expression of IGFBP4 mRNA | CTD | PMID:22714537 | niclosamide | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Niclosamide results in increased expression of IGFBP4 mRNA | CTD | PMID:36318118 | nitrofen | increases expression | EXP | | 6480464 | nitrofen results in increased expression of IGFBP4 mRNA and nitrofen results in increased expression of IGFBP4 protein | CTD | PMID:20938897 | ochratoxin A | decreases expression | EXP | | 6480464 | ochratoxin A results in decreased expression of IGFBP4 mRNA | CTD | PMID:18417182 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of IGFBP4 mRNA | CTD | PMID:25729387 | oxaliplatin | increases expression | EXP | | 6480464 | oxaliplatin results in increased expression of IGFBP4 mRNA | CTD | PMID:25729387 | p-menthan-3-ol | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Menthol results in decreased expression of IGFBP4 mRNA | CTD | PMID:26760959 | paclitaxel | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | CTD | PMID:16896004 | paclitaxel | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Paclitaxel results in increased expression of IGFBP4 mRNA | CTD | PMID:19682730 | paracetamol | decreases expression | EXP | | 6480464 | Acetaminophen results in decreased expression of IGFBP4 mRNA | CTD | PMID:33387578 | parathion | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Parathion results in increased expression of IGFBP4 mRNA | CTD | PMID:34813904 | pentane-2,3-dione | increases expression | EXP | | 6480464 | 2 and 3-pentanedione results in increased expression of IGFBP4 mRNA | CTD | PMID:25710175 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of IGFBP4 mRNA more ... | CTD | PMID:36331819 | perfluorooctanoic acid | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Plasticizers co-treated with Cosmetics co-treated with Flame Retardants co-treated with perfluorooctanoic acid co-treated with Phytoestrogens] results in decreased expression of IGFBP4 mRNA | CTD | PMID:33325755 | phenylephrine | affects response to substance | EXP | | 6480464 | IGFBP4 protein affects the susceptibility to Phenylephrine | CTD | PMID:11159833 | phytoestrogen | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Plasticizers co-treated with Cosmetics co-treated with Flame Retardants co-treated with perfluorooctanoic acid co-treated with Phytoestrogens] results in decreased expression of IGFBP4 mRNA | CTD | PMID:33325755 | picoxystrobin | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | picoxystrobin results in decreased expression of IGFBP4 mRNA | CTD | PMID:33512557 | pirinixic acid | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [pirinixic acid co-treated with PPARA] results in decreased expression of IGFBP4 mRNA and PPARA protein promotes the reaction [pirinixic acid results in decreased expression of IGFBP4 mRNA] | CTD | PMID:20059764 and PMID:20813756 | pirinixic acid | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of IGFBP4 mRNA | CTD | PMID:20059764 more ... | potassium chloride | affects response to substance | EXP | | 6480464 | IGFBP4 protein affects the susceptibility to Potassium Chloride | CTD | PMID:11159833 | potassium chromate | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of IGFBP4 mRNA | CTD | PMID:22714537 | progesterone | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Estradiol co-treated with Progesterone] results in decreased expression of IGFBP4 mRNA | CTD | PMID:20660070 | pyrimidifen | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | pyrimidifen results in increased expression of IGFBP4 mRNA | CTD | PMID:33512557 | quercetin | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Quercetin results in increased expression of IGFBP4 mRNA | CTD | PMID:21632981 | raloxifene | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Raloxifene Hydrochloride affects the expression of IGFBP4 mRNA | CTD | PMID:14699072 | resveratrol | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of IGFBP4 mRNA more ... | CTD | PMID:16338976 and PMID:23557933 | resveratrol | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | resveratrol results in decreased expression of IGFBP4 mRNA | CTD | PMID:23224687 | rifampicin | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA | CTD | PMID:21127053 | rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of IGFBP4 mRNA | CTD | PMID:28374803 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | IGFBP4 (Homo sapiens) | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | Salinomycin | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | salinomycin results in decreased expression of IGFBP4 mRNA | CTD | PMID:19682730 | selenium atom | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Selenium results in increased expression of IGFBP4 mRNA | CTD | PMID:19244175 | senecionine | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | senecionine results in decreased expression of IGFBP4 protein | CTD | PMID:35357534 | sodium arsenite | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of IGFBP4 mRNA | CTD | PMID:29301061 | sodium dichromate | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | sodium bichromate results in decreased expression of IGFBP4 mRNA | CTD | PMID:22561333 | sodium dichromate | increases expression | EXP | | 6480464 | sodium bichromate results in increased expression of IGFBP4 mRNA | CTD | PMID:22561333 | succimer | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in decreased expression of IGFBP4 mRNA and [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of IGFBP4 mRNA | CTD | PMID:21641980 and PMID:26378955 | sulforaphane | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [sulforaphane affects the susceptibility to Oxygen] which affects the expression of IGFBP4 mRNA | CTD | PMID:30529165 | T-2 toxin | decreases expression | EXP | | 6480464 | T-2 Toxin results in decreased expression of IGFBP4 mRNA | CTD | PMID:26141394 | tamoxifen | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Tamoxifen affects the expression of IGFBP4 mRNA | CTD | PMID:14699072 | tamoxifen | affects expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Tamoxifen affects the expression of IGFBP4 mRNA | CTD | PMID:17555576 | tert-butyl hydroperoxide | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | tert-Butylhydroperoxide results in increased expression of IGFBP4 mRNA | CTD | PMID:15336504 | tetrachloromethane | affects expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Carbon Tetrachloride affects the expression of IGFBP4 mRNA | CTD | PMID:17484886 | tetrachloromethane | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of IGFBP4 mRNA] | CTD | PMID:31150632 | tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of IGFBP4 mRNA | CTD | PMID:31150632 | thapsigargin | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Thapsigargin results in decreased expression of IGFBP4 protein | CTD | PMID:24648495 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of IGFBP4 mRNA | CTD | PMID:34492290 | titanium dioxide | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of IGFBP4 mRNA | CTD | PMID:23557971 | titanium dioxide | multiple interactions | ISO | Igfbp4 (Mus musculus) | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP4 mRNA | CTD | PMID:29950665 | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of IGFBP4 mRNA | CTD | PMID:25729387 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of IGFBP4 mRNA | CTD | PMID:25729387 | Triptolide | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | triptolide results in decreased expression of IGFBP4 mRNA | CTD | PMID:32835833 | triptonide | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | triptonide results in decreased expression of IGFBP4 mRNA | CTD | PMID:33045310 | tris(2-butoxyethyl) phosphate | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | tris(2-butoxyethyl) phosphate affects the expression of IGFBP4 mRNA | CTD | PMID:29024780 | troglitazone | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | troglitazone results in increased expression of IGFBP4 mRNA | CTD | PMID:28973697 | tungsten | decreases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Tungsten results in decreased expression of IGFBP4 mRNA | CTD | PMID:30912803 | valproic acid | affects expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of IGFBP4 mRNA | CTD | PMID:25979313 | valproic acid | increases expression | ISO | Igfbp4 (Mus musculus) | 6480464 | Valproic Acid results in increased expression of IGFBP4 mRNA | CTD | PMID:24896083 | valproic acid | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of IGFBP4 mRNA | CTD | PMID:29154799 | vanadium atom | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Vanadium results in decreased expression of IGFBP4 mRNA | CTD | PMID:19000753 | vanadium(0) | decreases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Vanadium results in decreased expression of IGFBP4 mRNA | CTD | PMID:19000753 | vitamin E | increases expression | ISO | IGFBP4 (Homo sapiens) | 6480464 | Vitamin E results in increased expression of IGFBP4 mRNA | CTD | PMID:19244175 | zinc atom | decreases expression | EXP | | 6480464 | Zinc deficiency results in decreased expression of IGFBP4 protein | CTD | PMID:10985758 | zinc(0) | decreases expression | EXP | | 6480464 | Zinc deficiency results in decreased expression of IGFBP4 protein | CTD | PMID:10985758 | |